BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

Pulse Biosciences (PLSE)Pulse BiosciencesEarnings

Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System Ended the quarter with $189 million of cash, cash equivalents, and marketable securities HAYWARD, Calif. --(BUSINESS WIRE)--Nov. 5, 2026-- Pulse Biosciences, Inc.

Related news

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

PRCTPROCEPT BioRobotics2026-11-04 21:05 EST

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

ACHCAcadia Healthcare2026-11-04 21:05 EST

Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance

STIMNeuronetics2026-11-04 12:50 EST

Neuronetics Reports Third Quarter 2026 Financial and Operating Results

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

AORTArtivion2026-10-22 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

STIMNeuronetics2026-10-21 12:30 EST

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-11-06 12:00 EST

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

PLSEPulse Biosciences2026-10-29 17:05 EST

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Stock data

Close
53.07 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States